PrecisionBiotics Ltd.   Report issue

For profit Phase 2
Founded: Cork Ireland (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2019
NCT04167475
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

PrecisionBiotics Group Ltd. | PrecisionBiotics Ltd.

Active Ingredients

Drugs in Phase 2 Trials (2)

bifidobacterium longum (2 trials)

magnesium stearate (1 trial)

Drugs in Other Trials (1)

alflorex® (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3